

Rank	Company / Fund Name	Ticker	Type	% Allocation
1	Rocket Lab Corporation	RKLB	Stock	10.0%
3	Abivax ADR	ABVX	Stock	8.0%
2	Global X China Robotics and AI ETF	CHIK	ETF	7.0%
4	Amazon	AMZN	Stock	7.0%
5	iShares Bitcoin Trust ETF	IBIT	ETF	7.0%
6	Xiaomi Corporation	1810.HK	Stock	7.0%
7	UiPath Inc.	PATH	Stock	6.0%
8	Global X Robotics & Artificial Intelligence ETF	BOTZ	ETF	6.0%
9	iShares MSCI China Small-Cap ETF	ECNS	ETF	6.0%
10	KraneShares CSI China Internet ETF	KWEB	ETF	5.0%
11	Alibaba Group Holding	BABA /9988.HK	Stock	5.0%
12	iShares Ethereum Trust ETF	ETHA	ETF	5.0%
13	Roundhill Humanoid Robotics ETF	ROBO	ETF	4.0%
14	iShares Future AI & Tech ETF	ARTY	ETF	4.0%
15	iShares Top 20 U.S. Stocks ETF	TOPT	ETF	4.0%
16	uniQure N.V.	QURE	Stock	3.0%

17	iShares International Country Rotation Active ETF	CORO	ETF	3.0%
18	Roundhill Magnificent Seven ETF	MAGS	ETF	3.0%

TOTAL: 100.0%

Investment Thesis & 2026 Catalyst
The company is targeting profitability in 2026 with the scheduled launch of its large-scale Neutron rocket and a massive \$805M defense contract backlog.
Anticipation is high for Phase 3 ulcerative colitis data in Q2 2026 and Phase 2b Crohn's disease developments mid-year, which could significantly re-rate the stock.
Focuses on China's A-share market, capturing the country's aggressive push into domestic automation and high-end manufacturing.
Analysts predict a major breakout in 2026 as AWS revenue reaccelerates (estimated 30% growth) due to massive AI infrastructure investments and potential Prime subscription price hikes.
Provides institutional-grade access to Bitcoin through traditional brokerage accounts, removing the technical and tax burdens of direct digital asset ownership.
The company continues to expand its "Artificial Intelligence of Things" (AIoT) ecosystem, with internal investment funds planned to begin incubating new tech in late 2026.
Positioned as a "rebound" candidate for 2026, it aims to leverage its discounted valuation and the broader integration of agentic AI into enterprise workflows.
Beneficiary of the "agentic AI" evolution, with exposure to leaders like Nvidia and a heavy tilt toward industrial robotics that are becoming cheaper and more widely adopted.
Gains from domestic Chinese manufacturing expansion, which recently hit 6-month highs as the region seeks to stabilize its growth.
A recovery play on Chinese consumer tech; specialized "defined outcome" versions of this fund are specifically structured to mature in January 2026 to manage volatility.
Major Chinese e-commerce platform with strong AI and cloud capabilities positioned for recovery as Chinese markets stabilize.
Provides institutional-grade access to Ethereum through traditional brokerage accounts, removing the technical and tax burdens of direct digital asset ownership.
Momentum is building toward a potential 2026 U.S. Executive Order providing federal funding for humanoid robotics to compete with China.
Provides targeted exposure to the entire AI value chain, including data centers and software, which are seeing massive capital expenditure increases through 2026.
Offers concentrated exposure to the "Magnificent Seven" and other mega-cap leaders that act as the primary profit engines for the U.S. market.
A speculative biotech play focused on gene therapy, having seen extreme volatility but high potential based on clinical trial milestones reaching maturity in 2026.

An actively managed fund that tactically rotates into non-U.S. markets (like Japan or India) that may outpace the U.S. in a high-rate environment.

Concentrated exposure to the Magnificent Seven technology leaders driving U.S. market performance in the AI era.